techniques that are largely used for protein interaction studies and the discovery of intracellular receptors, such as affinity-capture complex purification and the yeast two-hybrid system, may produce inaccurate data sets owing to protein insolubility, transient or weak protein interactions or irrelevant intracellular context. a versatile tool for overcoming these limitations, as well as for potentially creating vaccines and engineering peptides and antibodies as targeted diagnostic and therapeutic agents, is the phagedisplay technique. We have recently developed a new technology for screening internalizing phage (iphage) vectors and libraries using a ligand/receptor-independent mechanism to penetrate eukaryotic cells. iphage particles provide a unique discovery platform for combinatorial intracellular targeting of organelle ligands along with their corresponding receptors and for fingerprinting functional protein domains in living cells. Here we explain the design, cloning, construction and production of iphage-based vectors and libraries, along with basic ligand-receptor identification and validation methodologies for organelle receptors. an iphage library screening can be performed in ~8 weeks.
IntroDuctIon
Over almost 3 decades, phage selection performed in vitro and in vivo has provided insight into the biology at the cell surface through the identification of novel functions for known proteins, novel multiprotein complexes and targetable expression patterns in normal and pathological settings [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Recently, we showed that intracellular ligand-directed delivery can be accomplished by the use of cell-penetrating peptides that induce receptorindependent crossing of eukaryotic cell membranes. These peptides are usually arginine-rich cationic sequences of 10-30 residues in length. One of the best-characterized peptides is penetratin (pen), which is derived from the third helix of the homeodomain of the Drosophila antennapedia protein [16] [17] [18] . Pen has been used to transport peptides, recombinant proteins, antibodies, small interfering RNAs and micro RNAs into cells [19] [20] [21] [22] [23] [24] [25] [26] .
The concept of an intracellular 'ZIP code' system has long been well established [27] [28] [29] [30] [31] . However, very few, if any, high-throughput discovery tools are currently available for the identification of intracellular ZIP codes. Here we use a recently introduced class of filamentous bacteriophage-based reagents that integrate recombinant pen as a fusion protein with a recombinant major coat protein (rpVIII), thereby enabling receptor-independent phage particle entry into, and intracellular distribution within, mammalian cells 32 . Moreover, either random peptide libraries or specific individual motifs can be displayed simultaneously on the minor coat protein (pIII), a feature allowing intracellular library selection and organelle targeting. We have named this new family of reagents iPhage vectors and libraries 32 . This integrated technology platform permits ligand-directed combinatorial selection and targeting of cell organelles and intracellular signaling/ metabolic pathways.
Peptide-based molecular probes identified by phage-display technology expand the peptide repertoire for in vivo diagnosis of and therapy for obesity, cancer and eye diseases. Numerous peptides that bind cancer-associated antigens have been discovered by affinity selection of ligands from phage-display random libraries. A few of the peptides selected by phage display are currently being developed toward preclinical and clinical applications [33] [34] [35] [36] [37] [38] . The success of phage-derived peptides depends on the quality of the library screen, functional assays and receptor validation. Here we describe the method for generating and screening the iPhage-display system and explain how to select and validate candidate internalizing homing peptide (iHoPe) ligands (Fig. 1) .
The iPhage methodology described here can also be integrated with the adeno-associated virus/phage (AAVP) constructs [39] [40] [41] [42] [43] [44] [45] to generate internalizing AAVP (iAAVP) vectors and libraries, which have been used for the isolation of blocking peptides for apoptosis-inducing drugs 46 and for RNA interference (RNAi) library screens 47, 48 . This new class of phage vector is under development in our laboratory and is based on a two-step cloning strategy: the first step is the generation of an iPhage vector containing a multicloning site (iPhage-MCS vector). Subsequently, pAAV containing the eukaryotic expression cassette of interest between flanking inverted terminal repeat (ITR) sequences is cloned into the iPhage-MCS. Furthermore, it may be possible to combine receptor-targeting peptides with intracellular bioactive peptides discovered by iPhage, thus creating the potential to modulate cell function in a tissue-and organ-specific fashion. The new resource introduced here can be used to target intracellular ZIP codes, interrogate signal transduction pathways and participate in the discovery and development of an organelle-targeted cell biology and pharmacology in mammalian cells.
Applications of the iPhage technology
The iPhage technology can be applied to the unbiased delineation of intracellular pathways, intracellular protein-protein complexes and organelle receptors in their native conformations.
Targeting mammalian organelles with internalizing phage (iPhage) libraries
The expression of the pen protein on the recombinant pVIII allows, in a receptorindependent fashion, the penetration of a complete phage library into mammalian cells in vitro; wellestablished peptide motifs expressed on the minor capsid protein pIII can thereby be delivered to different subcellular locations. Note that for the purposes of this protocol we describe the step-by-step separation of the mitochondria fraction and the identification and validation of mitochondria-ligand peptides. However, separation of the nuclear and cytosolic fractions after iPhage library panning, bioactive iPhage particle identification and peptide sequence selection can also be achieved by following the same guidelines described herein. Ultimately, bioactive intracellular peptide ligands identified by iPhage can be tailored to other targeting entities for tissue selectivity.
Limitations of the iPhage technology
Identification of a target or protein receptor by phage display relies mostly on an effective way to separate specific from nonspecific binders. In conventional in vitro phage-display panning, removal of nonspecific binders can be easily achieved by thorough wash steps. In the case of iPhage, however, the entire phage library enters the cell, and the identification of specifically bound phage requires distinct and systematic approaches. The proper isolation of organelles will determine the enrichment of specific peptide sequences in subcellular fractions and will have an effect on the identification and validation of ligand/receptor pairs.
Our studies with iPhage suggest that mainly soluble proteins and the surfaces of organelles are targetable using this technology. The binding properties of iPhage toward single-pass or integral membrane proteins, or the ability of iPhage particles to target a given organelle's internal space (lumen), such as the mitochondrial matrix, are yet to be evaluated. Thus, iPhage panning, identification and receptor validation data must be analyzed carefully. Further and complementary experiments such as electron microscopy studies must be performed to ascertain whether iPhage can cross the membrane of the organelle of interest. Similarly, novel ligand peptides and receptors should be confirmed functionally.
Advantages of the iPhage technology
Several approaches for the discovery of peptides with intracellular functions have been developed in the past few years. For example, retroviral expression of peptide libraries in mammalian cells guided the isolation of blocking peptides for cell death-inducing drugs 46 ; the same screening system coupled to fluorescent markers identified organelle-homing peptides with useful biological properties 49 . Similarly, many systematic approaches have been used to interrogate intracellular pathways and activities, including shRNA and RNAi library screening 47, 48 and yeast (two)-hybrid techniques 50, 51 . The former screen identifies genes involved in specific processes but does not place them in context (e.g., upstream, downstream or at the nexus of the specific function assayed). The latter identifies putative binding moieties and interaction networks, and provides better context, but lacks direct functional insight because only binding partners are identified.
Conversely, in the past decade, the combinatorial phagedisplay technology has expanded in its application to deciphering the molecular diversity of peptide-binding specificity to isolated proteins, purified antibodies, cell surface receptors, intracellular and cytodomains, and blood vessels in vivo 52 in an unbiased functional manner without any preconceived notion of the nature of the target. Moreover, the phage-display technology, including iPhage, is a relatively inexpensive methodology, in which libraries can be easily obtained. Furthermore, the technique is simple, can be rapidly set up and requires no special equipment.
Our initial studies with iPhage have identified peptides that have the potential to modulate cell function in a tissue-and/or organ-specific manner after organelle-specific delivery (for example, via the triggering of apoptosis) 32 . These data suggest that iPhage is a valuable tool for the interrogation and evaluation of intracellular molecular interactions, thereby enabling direct targeting of intracellular organelles and metabolic or signaling pathways in living cells, as well as allowing the selection of bioactive peptides from virtually any subcellular fraction and organelle.
Experimental design
Generation of the iPhage peptide library. The construction of iPhage random peptide libraries is based on cloning DNA fragments encoding peptide sequences into the phage genome fused to the pIII coat protein gene (Fig. 2) . Incorporation and expression of the gene fusion product result in the presentation of the peptide on the phage surface, on which it can interact with and bind to a potential target. A phage library can consist of up to 10 9 unique phage clones, each displaying a different peptide. The size of the peptide insert and its expression orientation (linear or cyclic) are two variations that can be adjusted to fit the purpose of the screen. In this protocol, we use a X 4 YX 4 (X, any residue; Y, tyrosine) linear library to exemplify the potential of the iPhage technology. In addition, the success of the screening is integrally dependent on how well the library is constructed. Although insertless phage cannot be avoided and will be eliminated in the phage selection biopanning procedures, it is important to limit the presence of insertless phage in the library to maintain library diversity.
The fUSE5 vector used in our studies was engineered to be noninfective by disruption of the gene III reading frame with a 14-bp 'stuffer' 53 . Infectivity is restored only when the stuffer sequence is replaced with an in-frame insertion. Removal of the fUSE5 stuffer sequence within gene III is achieved by digestion with the restriction enzyme SfiI (Fig. 2) . This process leaves two overhanging sites incompatible with each other, thereby allowing the unidirectional cloning of the DNA insert 53 . In addition, it is important to note that the f88-4 display vector contains two VIII genes, encoding two different types of pVIII molecules. One pVIII is recombinant, fused to pen, and the other is wild type (WT). The recombinant gene (r)pVIII is synthetic and differs in its nucleotide sequence from the WT gene (Fig. 2) . Because the recombinant gene VIII is transcribed from a tac promoter, full expression in a lacI Q strain, such as K91Blu/kan Escherichia coli, requires the inducer IPTG (1 mM) and the absence of glucose. In a lacI strain, such as MC1061 E. coli, the IPTG is not necessary. For the purification of f88-4, fUSE5 and iPhage vectors, we recommend using a cesium chloride density gradient (Fig. 3a) . This method yields ultraclean, highquality phage plasmid preps appropriate for cloning of pen, construction of the chimera vector and iPhage library construction (Fig. 3b) . However, if long spinning times and the use of ethidium bromide are the major drawbacks, we recommend purifying the phage plasmid twice on a Qiagen 500-tip to yield cleaner DNA preps.
Because the library quality and diversity rely on the cloning protocol, we recommend adding both the phage vector and insert into the tubes, mixing them with Milli-Q water and warming them to 50 °C for 3 min to melt any cohesive termini that have reannealed during DNA purification. Chill the DNA solution on ice before the rest of the ligation reagents are added. Purification of the ligated products and recovery in water allow high electroporation efficiency in the MC1061 E. coli strain.
Screening, selection and receptor validation of candidate iPhage clones. The screening of a phage library consists of three main steps: (i) introduction of phage particles to an immobilized target, in this case the Kaposi sarcoma (KS) 1767 cell line 54 ; (ii) removal of unbound phage by washing; and (iii) elution of the bound phage. Ideally, one cycle of selection should be sufficient, although in practice several rounds are necessary (typically two to four) to isolate target-specific binders. DNA sequencing is used to monitor enriched peptide frequency compared with the unselected library. Next, the peptide of interest is synthesized and used to identify and ultimately validate the receptor candidate (Fig. 4) . Enriched peptide sequences can also be further analyzed by comparison with a publically available peptide database (e.g., Basic Local Alignment Search Tool-BLAST) to identify proteins and/or ligands with the same sequence as the peptide.
For successful iPhage biopanning, we recommend titering the iPhage library or iPhage clone no longer than 1 week before each experiment to ensure that an accurate number of iPhage particles is used. When iPhage biopanning is done on a cell line, cells must Random peptide iPhage display library
Ligation of library and iPhage
Step 16
Step 18
Step 25
Step Steps 33 and 37
Step 48
Step Step 90
Elute the protein complex, associated with the crosslinked-peptide, with excess of ligand peptide.
Step 91
Screen washed and eluted fractions by phage-binding assay and identify the fraction containing the candidate receptor.
Step 94
Analyze fraction in Tris-glycine gels. Compare positive fraction with negative fractions and isolate unique bands.
Step 103 combinatorial phage-display screenings. Several factors can influence the results of the assays. For example, the molecular interaction between the peptide and receptor can be influenced by the amount of immobilized protein, the affinity of the peptide ligand for its receptor, ionic strength, the conformation of the protein, the existence of protein complexes and temperature. During the phage-binding assay, the cell lysates must be prepared with nondenaturing (i.e., nonionic) detergents such as Triton X-100, NP-40 or Tween 20 to disrupt the cell membrane integrity, thereby facilitating the lysis and extraction of soluble proteins, yet maintaining the native structural conformations and protein complexes. Protease inhibitors should also be used to prevent protein degradation. Subcellular fractions, prepared by the differential centrifugation method [55] [56] [57] (Fig. 5a ) or commercially available cell fractionation kits (e.g., ProteoExtract subcellular proteome extraction kit, Millipore, cat. no. 539790), must be tested by western blotting for specific markers such as cadherin (membrane marker), hydroxysteroid (17-) dehydrogenase 10 (ERAB; mitochondrial marker), high-mobility group box 1 (HMGB1; nuclear marker) and actin (cytosol marker) to ensure proper organelle or compartment enrichment (Fig. 5b) . Further subcellular fractionation techniques [57] [58] [59] [60] [61] to obtain highly pure subcellular fractions, such as sucrose density gradient centrifugation 57 may be applied and are compatible with the iPhage technology. The use of either PBS or Tris-buffered saline for the phage-binding assays is recommended. Note that other buffers can be used, but optimization would be required. The blocking solution (BSA) should always be filtered (0.22-µm-pore filter) because this procedure minimizes nonspecific control phage binding and bacterial colony background. In the immunocapture assay, a crucial factor is the determination of candidate receptor expression levels. Lysates obtained from the cell line screened should always be tested by western blotting to define the source of the protein extract. In addition, 
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Box 1 | Rapid phage quantification (qPhage) • tIMInG 2 h
In this procedure, phage content is determined by qPCR. Dilute the iPhage clone or library sample to 1:10,000 in Milli-Q water. different concentrations of immobilized antibodies as well as cell extracts should be tested to determine optimal conditions before performing the immunocapture assay. It is important to ascertain the amount of immobilized protein on the plate. The best concentration for the assay can be estimated by a protein assay (Bradford or bicinchoninic acid assay (BCA)) or by serial protein dilutions.
During affinity chromatography, multiple protein bands are often co-purified, indicating that the candidate receptor might be found in association with other molecular components (Fig. 4) . Tandem mass spectrometry (MS/MS) and bioinformatics analysis (i.e., DAVID 62 , String 63 or Ingenuity Pathway Analysis (IPA) http://www.ingenuity.com/products/ipa) should indicate whether the proteins purified were previously reported to form protein complexes.
Rapid phage quantification. In this protocol, we used the traditional phage display method of phage quantification by counting transduced units and individual sequencing of phage clones. However, to eliminate the reliance on host bacteria, one can use real-time PCR for rapid phage quantification (qPhage) 64 . The qPhage protocol is described in Box 1 and can be used to replace the traditional colony count method in Steps 57, 72, 77 and 94. Note that with the qPhage method, template optimization may be required.
MaterIals
REAGENTS
Plasmids: fUSE5 (GenBank: AF218364) and f88-4 (GenBank: AF218363.1) phage plasmids 53, 65 • 
2|
Immediately remove the cuvette and add 1 ml of SOC medium. With a Pasteur pipette, transfer the cell suspension into a 1.5-ml tube and incubate it at 37 °C for 1 h.
3|
Plate 100 µl of serial dilutions (1:10, 1:100 and 1:1,000) on LB-tetracycline (tet) (40 µg ml −1 ) plates, and incubate the plates overnight at 37 °C. Note that E. coli transformed with phage vectors grow slower and might require longer incubation times to obtain visible colonies.  pause poInt Bacterial plates remain stable for at least 1 week when wrapped with Parafilm and stored at 4 °C.
4|
Prepare a seed culture from a single colony in 5 ml of LB-tet (40 µg ml −1 ) medium, and grow it in agitation (225-250 r.p.m.) for 8 h at 37 °C.
5|
Add the starter culture to 500 ml of LB-tet medium (40 µg ml −1 ) and agitate the culture at 250 r.p.m. for 12-18 h at 37 °C. Use a 2-liter flask to provide sufficient air for the overnight culture. The culture should reach a cell density of ~3-4 × 10 9 cells per ml, which typically corresponds to a pellet wet weight of ~3 grams per liter of medium.
6|
Centrifuge the culture at 6,000g for 15 min at 4 °C, and then purify the culture with the maxiprep plasmid purification kit according to the manufacturer's instructions.  crItIcal step To increase the plasmid yield, warm the elution buffer to 50 °C. ? troublesHootInG  pause poInt If desired, cell pellets can be stored at −20 °C for 12 h.
7|
Prepare a 1:100 dilution of the DNA, mix it well and measure the optical density at 260 nm (OD 260 ) in a spectrophotometer blanked against 10 mM Tris-HCl (pH 7.5). Calculate the concentration of DNA using the following formula:
DNA( g/ l)= OD 50 g/ml dilution factor 1,000 260 µ µ × µ × 8| Measure the plasmid DNA volume, and, for each ml of plasmid DNA, add 1.1 g of CsCl and 100 µl of ethidium bromide, 10 mg ml −1 (the volume will increase by 25-30%). Dissolve the CsCl by mixing gently. Cover the sample with aluminum foil and incubate it at room temperature for 30 min. ! cautIon Ethidium bromide is a potent mutagen. It may be fatal if inhaled and is harmful if swallowed or absorbed through skin. It causes irritation to the eyes, respiratory tract and skin. It may cause heritable genetic damage. Wear gloves and safety glasses while working with it. It must be handled with extreme caution and decontaminated on activated charcoal or Amberlite ion exchange resins before disposal.  crItIcal step Perform the following steps under low light intensity to avoid DNA mutations due to ethidium bromide exposure.
9|
To remove any precipitate present in the CsCl/DNA solution, spin the tubes at 6,000g for 5 min at room temperature (debris may either float or sink). Carefully transfer only the clear reddish supernatant into a Quick-Seal ultracentrifuge test tube. By using a 20-gauge syringe, completely fill the tube by adding the equivalent TE/CsCl/ethidium bromide solution (i.e., without DNA) as prepared in Step 8. Dry the neck of each tube, place metal caps on the tubes, heat-seal them and recheck the balance. Place each tube and its counterbalance tube in an ultracentrifuge rotor (e.g., VTi65.2 rotor). Spin the tubes at 176,000g for 48 h at 20 °C.  crItIcal step It is advisable to first practice sealing on tubes filled only with water. Check each seal by pointing the top of the tube into the sink and applying pressure. Failure to seal tubes appropriately may cause the tubes to collapse during ultracentrifugation.
10|
Carefully remove the tubes from rotor so as to not disturb the gradient. Follow the methods detailed in Sambrook and Russell 66 to assemble the materials used to extract the plasmid DNA. In summary, with an 18-gauge needle, make a vent in the tube by puncturing it at the top; leave the needle hanging in the tube to prevent leakage. Pull out the lower plasmid band (the lower band contains the double-stranded plasmid; the upper band contains the single-stranded DNA) with an 18-gauge needle attached to a 1-ml syringe (Fig. 3a) . Place the DNA in a 15-ml conical tube.  crItIcal step To avoid DNA shearing during sample collection, remove the needle from the syringe and transfer the plasmid DNA into a clean 50-ml collection tube. Repeat this as many times as necessary.
? troublesHootInG 11| Measure the sample volume and mark its level on the surface of the collection tube. Remove the ethidium bromide by adding 15 ml of 2-propanol per 1 ml of CsCl/DNA solution. Vortex the tube for 10 s (a fluffy white precipitate will appear) and centrifuge the tube at 1,800g for 1 min at room temperature to separate the phases. Remove the upper phase (pink; isopropanol) and add TE buffer up to the mark indicating the original volume. Mix the sample until the precipitate is dissolved. Repeat the process until the pink color disappears (three or four times), each time adding TE as necessary.
12|
In a 50-ml conical tube, measure the final plasmid DNA volume and add 2.5 volumes of fresh TE to the sample. Mix the sample thoroughly. Add 2 volumes of ethanol (e.g., 3.5 ml of original DNA solution + 7.0 ml ethanol); vortex and incubate the sample at − 20 °C for at least 2 h.  pause poInt DNA can be precipitated overnight at −20°C.
13|
Centrifuge the sample at 15,000g for 30 min at 4 °C. Decant all the ethanol, air-dry the pellet and resuspend the sample with 500 µl of 10 mM Tris-HCl (pH 8.0). Measure the DNA concentration as previously described in Step 7. 24| Place the agarose-DNA fragments in 1.5-ml microcentrifuge tubes, and purify the fragments with the QIAquick gel-extraction kit according to the manufacturer's protocol. Measure the DNA concentration as described in Step 7. Step 27, and incubate the plate overnight at 37 °C. Pick a single colony from the freshly streaked plate, inoculate the bacteria into 5 ml of LB-tet (40 µg ml − 1 ) medium and follow the procedure for phage plasmid isolation and purification (Steps 4-13).
25|
? troublesHootInG 29| Inoculate a seed culture of electrocompetent MC1061 E. coli for overnight growth in 10 ml of SOB containing 50 µg ml − 1 streptomycin sulfate.
30| Dilute 2 ml of the overnight culture into 2 liters of SOB (without magnesium) supplemented with 50 µg ml − 1 of streptomycin. Distribute the 2-liter culture into four 2-liter flasks (500 ml per flask), and grow bacteria at 37 °C under agitation (250 r.p.m.). Monitor the bacterial growth until its optical density reaches 0.8 at 600 nm (around 3-4 h of culture).
Immediately centrifuge the bacteria cells at 6,000g for 10 min at 4 °C.
31|
Wash the bacterial pellet twice with 150 ml of ice-cold 10% (vol/vol) glycerol diluted in ddH 2 O; centrifuge the pellet at 6,000g for 15 min at 4 °C.  crItIcal step Keep all solutions cold and maintain the bacteria on ice at all times. 
34|
After digestion, the SfiI restriction enzyme will generate nonidentical, noncomplementary three-base 3′-overhangs. Run the linearized iPhage plasmid on an E-Gel (0.8%, wt/vol) for 30 min at 200 V to confirm digestion. Digestion with SfiI will linearize the 9,300-bp-long iPhage plasmid into one single 9,300-bp fragment. In the agarose gel, the single linear iPhage plasmid will appear to migrate more slowly than the same plasmid when circular, thereby resulting in a higher DNA band (linear plasmid) and a lower DNA band (circular plasmid). Purify the digested iPhage vector with the gel-extraction kit according to the manufacturer's instructions. This step allows the complete removal of the 14-bp DNA stuffer (5′-TGGCCTGGCCTCTG-3′) located in the pIII gene. Measure the DNA concentration as described in 
36|
Purify and elute the PCR products (the library PCR-insert) containing BglI restriction sites using the QIAquick nucleotide removal kit according to the manufacturer's instructions. Measure the DNA concentration at OD 260 .
37| Digest 1 µg of library PCR insert with 100 units of BglI restriction enzyme in a final volume of 50 µl, as described in
Step 16 or 22. Incubate the reaction mixture overnight at 37 °C.
38| Purify, elute and measure the concentration of the BglI-digested PCR inserts as described in Step 36.
39|
To determine the optimal vector:insert molar ratio, perform test ligations with 50 ng of linearized iPhage vector and different BglI-digested PCR-insert ratios (1:1, 1:3, 1:5 and 1:10), as described in Step 18. In addition, set up a reaction with the linearized iPhage plasmid alone to estimate the level of bacterial transformation due to nondigested iPhage plasmid. 
49|
Combine the electroporations into 380 ml of prewarmed SOC medium. Gently agitate (150 r.p.m.) the bacteria at 37 °C for 1 h.
50|
Add the 400 ml of culture (Step 49) to 3.6 liters of LB-tetracycline (40 µg ml − 1 )/streptomycin (50 µg ml − 1 ), and then divide the culture into eight 2-liter baffled Fernbach flasks (500 ml per flask) to provide sufficient air for the overnight culture. Agitate the culture (250-300 r.p.m.) at 37 °C for 12-18 h.
51|
Transfer the culture into eight 500-ml centrifuge bottles and centrifuge it at 6,000g for 15 min at 4 °C. Transfer the supernatants into clean centrifuge bottles and store them at 4 °C. Recover and wash the bacterial pellets with 500 ml of ice-cold 10% (vol/vol) glycerol, centrifuge the pellets at 6,000g for 15 min at 4 °C and repeat. After the second centrifugation, resuspend the pellet in 2 ml of 50% (vol/vol) glycerol and distribute the cells into ten chilled 0.5-ml centrifuge tubes (0.2 ml per tube). Snap-freeze the pellets in liquid nitrogen and store the samples at − 80°C.  crItIcal step The bacterial pellets are used for library amplification. A comprehensive library amplification protocol is described in box 2.
52|
To remove residual bacterial debris, centrifuge the supernatants at maximum speed at 4 °C for 20 min. Collect and transfer the supernatants into four clean 2-liter flasks (1 liter per flask). Add 150 ml of PEG-NaCl solution into 1 liter of supernatant (0.15 volume of PEG-NaCl per volume of supernatant) to precipitate the iPhage particles; stir overnight at 4 °C.
53|
Transfer the precipitation solution equally into ten clean 500-ml centrifuge bottles, and then centrifuge the bottles at 10,000g for 30 min at 4 °C. A white pellet should be obtained. In each tube, discard the supernatant and centrifuge the samples again at 10,000g for 10 min. Carefully decant the supernatants.
54|
Resuspend each iPhage pellet in 2 ml of sterile PBS and combine the pellets into a 50-ml conical tube. Centrifuge the tube at 10,000g at 4 °C for 10 min, discard the pellet and transfer the iPhage solution into a new 50-ml conical tube.
55|
Repeat the precipitation by adding 3 ml of PEG-NaCl solution (0.15 volume) into 20 ml of the iPhage suspension for 1 h on ice. Centrifuge the suspension at 10,000g for 30 min at 4 °C, and then resuspend the pellet in 0.5-1 ml of PBS, depending on the size of the pellet.
56|
Transfer the solution into a 1.5-ml microcentrifuge tube, and then centrifuge the tube at 14,000g for 10 min at 4 °C. Discard the pellet and transfer the supernatant into a new 1.5-ml microcentrifuge tube. Recentrifuge the tube to remove residual bacteria and debris. Discard the pellet. Filter the resulting supernatant containing the iPhage library particles through a 0.45-µm filter. 
Alternatively, the qPhage protocol may be used for iPhage titration (box 1).  crItIcal step K91/kan E. coli viability has an important role in iPhage titration. Always infect bacteria growing in log phase with an OD ranging between 1.6 and 2.0 at a wavelength of 600 nm (OD 600 ).
? troublesHootInG  pause poInt iPhage titers are relatively stable; the preparations can be stored at 4 °C for long periods of time (several months) without a substantial decrease in the titers. For longer storage times, one should check the titer of the preparation before use. Gently agitate the flask to cover the cell monolayer evenly. Incubate the flask overnight at 37 °C in a 5% CO 2 .
60| On the following day, warm 0.05% (wt/vol) trypsin-EDTA, PBS and complete growth medium in a 37 °C water bath. Remove and discard the iPhage/growth medium from the culture flask with a sterile pipette. Wash the cells with 10 ml of warm PBS to remove any remaining medium. Replace the PBS with 3 ml of trypsin-EDTA. Incubate the flask for 10 min at room temperature. Check the culture with an inverted optical microscope to ensure that the cells are detached from the surface.
61|
Neutralize the trypsin-EDTA by adding 10 ml of warm growth medium. Draw the cell suspension with a sterile pipette. Rinse the inside surface of the flask several times with the cell suspension to ensure that most of the cells are in suspension.
Check under an inverted optical microscope if necessary. Transfer the cell suspension into a 15-ml conical tube, and then centrifuge the tube at 150g for 5 min at room temperature. Wash the cell pellet three times with ice-cold PBS to remove traces of trypsin-EDTA and growth medium. Resuspend the pellet in 1 ml of PBS.
62|
Mix the pellet suspension (1 ml) with 11 ml of ice-cold hypotonic buffer. Transfer the cell suspension into a Dounce homogenizer and incubate it for 10 min on ice.
63|
To disrupt the membranes, perform 15 up-and-down strokes with a loose-fitting pestle and 25 up-and-down strokes with a tight-fitting pestle on the KS1767 cells; add 8 ml of 2.5× mitochondrial stabilization buffer. Seal the tube with Parafilm and mix it thoroughly by inversion.
64|
Divide the 20-ml cell lysate suspension into ten 2-ml ice-cold microcentrifuge tubes, and then centrifuge the tubes at 1,300g for 5 min at 4 °C. Recover and transfer the supernatant into clean microcentrifuge tubes. Centrifuge the samples twice more. The pellet contains the nuclei, intact cells and large membrane fragments.
65|
Transfer the supernatants into clean 2-ml microcentrifuge tubes and pellet the mitochondria at 17,000g for 15 min at 4 °C. Wash the mitochondria by resuspension of the pellets in 500 µl of MS buffer. Centrifuge the samples once more at 17,000g for 15 min at 4 °C. Discard the supernatants and keep the mitochondrial pellets on ice.  crItIcal step If the iPhage recovery (Step 66) is done on the same day, we recommend starting a K91/kan E. coli culture (Step 57) 2-3 h before the subcellular fractionation (Step 62).  pause poInt Mitochondrial pellets can be stored at −80 °C for further assays.
66|
Add 200 µl of the K91/kan E. coli onto each mitochondrial pellet aliquot (ten aliquots in total;
Step 65). With a micropipette, gently resuspend and mix the pellet. Incubate the sample for 1 h at room temperature.
67|
Transfer the 200 µl of bacteria + pellet into 10 ml of prewarmed LB medium supplemented with 40 µg ml − 1 of tetracycline and 100 µg ml − 1 of kanamycin; incubate the sample for 30 min at room temperature.
68| Dilute the sample into 1:10, 1:100 and 1:1,000. Plate 10 µl of each dilution in triplicate onto LB-tet/kan plates and incubate the plates overnight at 37 °C. Transfer the remaining culture (~10 ml) into 300 ml of prewarmed LB-tet/kan containing 1 mM IPTG and incubate it overnight at 37 °C.
69|
Pick single colonies and proceed to iPhage PCR and insert sequencing (Step 73). Alternatively, colony plates can be stored at 4 °C and processed together after the last iPhage screening round is complete (Step 72).
phage recovery by salt precipitation • tIMInG 1 d 70| Centrifuge the bacterial culture (
Step 68) at 6,000g for 20 min at 4 °C, and then transfer the supernatant into new bottles containing 0.15 volumes of PEG-NaCl solution (e.g., 45 ml of PEG-NaCl:300 ml of culture). Incubate the samples for 2 h on ice. After incubation, follow Steps 53-55.
71|
After the second phage precipitation (Step 55), centrifuge the samples at 10,000g for 30 min at 4 °C. Carefully decant the supernatant and resuspend each iPhage pellet in 100 µl of PBS. For each sample, recover and transfer the resuspended iPhage particles into a clean 1.5-ml microcentrifuge tube. To remove insoluble material, centrifuge all samples at 14,000g for 10 min at 4 °C, and transfer each supernatant into a sterile 1.5 ml-microcentrifuge tube.
72|
Filter the iPhage particles through a 0.22-µm filter and titrate the iPhage particles as described in Step 57. Alternatively, the qPhage protocol may be used to replace the colony count method (box 1). Store the iPhage particles at 4 °C for further rounds of selection on KS167 cells. On the basis of our studies, a total of three rounds of selection are necessary to enrich specific peptide sequences and reduce the false-positive ligands. For each round of selection, follow Steps 58-71.  pause poInt The recovered iPhage particles are stable for at least 2 weeks without the reduction in titer.
pcr sequencing of iphage inserts • tIMInG 1 d 73| The peptide identity is determined by sequencing the DNA corresponding to the insert in the recombinant pIII. Thus, to determine the insert sequence of recovered iPhage clones, pick 96-wellseparated bacterial colonies from each round of selection (Step 68). For each round, prepare a 96-well U-bottom plate and inoculate each colony in 50 µl of 30% (vol/vol) glycerol-LB. Store the plates at −80 °C.
74|
Prepare a PCR reaction as described below. For high-throughput screening, use a 96-well PCR plate. Include an iPhage without an insert as a negative control. 75| Run 2 µl of ten PCRs randomly selected from each PCR plate on a 2% (wt/vol) E-Gel. Positive iPhage colonies will have PCR products of around 300 bp long, whereas the negative control will generate a PCR product of around 250 bp long. Prepare a 1:10 dilution with water from each PCR, and then submit the samples for nucleotide sequencing with the pIIIseq Rev primer (table 1). The peptide sequences and sequence enrichment are analyzed with bioinformatics tools and are described elsewhere 62 .
amplification of iphage clones • tIMInG 3 d 76| iPhage clones of choice can be amplified by inoculation of 3 ml of LB-tet/strep containing 1 mM IPTG with 1 µl of the bacteria glycerol stock (Step 73) and incubation of the seed culture at 37 °C for 8 h. Transfer the seed culture into 100 ml of LB-tet/strep containing 1 mM IPTG and follow the iPhage-precipitation protocol as described in Steps 52-56.
77|
Titrate each iPhage clone (Step 57) for no more than 1 week before performing the cell viability assay. Alternatively, iPhage titration may be achieved by using the qPhage protocol as described in box 1. 79| Remove the growth medium and avoid disturbing the cell monolayer. Carefully add 100 µl of complete growth medium containing 1 × 10 9 TU of iPhage in triplicate, and then incubate the plate overnight at 37 °C in 5% CO 2 . Include insertless iPhage and YKWYYRGAA-iPhage 32 as negative and positive controls, respectively. The oligonucleotide sequence that encodes the YKWYYRGAA peptide is depicted in the TPL primer in table 1.
80| After 24 h, take ten random phase-contrast microscopy images from each triplicate and determine cell viability by adding 10 µl of MTT (12 mM) according to the manufacturer's instructions. Alternatively, cell viability may be determined by the WST-1 assay according to the manufacturer's protocol.
81|
Mix each sample thoroughly with a micropipette and measure the optical density at 570 nm. Plot the data and correlate it with the cell density/morphology images obtained by phase-contrast microscopy. Bioactive iPhage can be selected on the basis of reduced cell growth rate and cell viability (measured by the MTT or WST-1 assays) as well as according to cell shrinkage or pyknosis (chromatin condensation) visible in light microscopy.
82|
Once the bioactive iPhage clone is identified, synthesize it in house or order its corresponding peptide ligand for further receptor identification and validation. We recommend a peptide purity of 95% and the use of acetate as a counter ion.
ligand receptor purification by affinity chromatography • tIMInG 2 d 83| Conjugate 10 mg of a bioactive peptide to a 2-ml agarose column matrix (CarboxyLink immobilization kit) according to the manufacturer's instructions.
84| Culture KS1767 cells to 90% confluence in six 175-cm 2 culture flasks. One day before use, replace the medium with complete growth medium and incubate the cells overnight at 37 °C in a 5% CO 2 .
85| Wash and detach the cells by standard tissue culture procedures.
86|
Wash each cell pellet once with 10 ml of plain MEM and resuspend the pellet in a 1:1 volume of ice-cold protein extraction buffer (i.e., 500 µl of MEM:500 µl of extraction buffer). Incubate the cell suspensions at 4 °C for 1 h on a rocking plate.
87|
Centrifuge the cell lysate (suspension) at 20,000g for 15 min at 4 °C; keep the supernatant on ice. Measure the protein concentration using the BCA protein assay kit according to the manufacturer's protocol.  pause poInt Cell protein extracts can be divided into aliquots and stored at −80 °C for at least 1 week.
88| Equilibrate the affinity column (prepared in
Step 83) and column buffer (see Reagent Setup) to room temperature. Equilibrate the column by adding 10 ml of column buffer that has been passed through the column.  crItIcal step Throughout the procedure, do not allow the resin to become dry. Replace the bottom cap as soon as the buffer drains down to the top of the resin bed.
89| Add 1-2 mg of total cell extract to the column (Step 87). Cap and seal the column at both ends with Parafilm. Rock the column for 1 h at room temperature.
90|
Place the column in a base support stand, remove the top and bottom caps from the column and wash it with 20 ml of column buffer. Monitor the optical density at 280 nm until it reaches 0.001. To remove any residual protein, wash the column with 10 ml of column buffer.
91| Elute the bound protein by adding 2 ml of the bioactive peptide (5 mM) diluted in column buffer and collect 0.5-ml fractions. Continually add 20 ml of column buffer to the column and monitor elution by optical density at 280 nm until it reaches 0.001 (~20 samples). The excess of bioactive peptide will compete with the protein complex associated with the peptide cross-linked to the column, and it will thereby release the protein receptor. 105| Use a clean scalpel to cut and transfer the gel fragments into a clean 1. 
antIcIpateD results
The iPhage technology is a unique platform for ligand-directed targeting of organelles and molecular pathways within live cells; it has applications ranging from fundamental cell biology to drug development. To create the chimeric iPhage vector, the backbone of phage vector f88-4 displaying the peptide RQIKIWFQNRRMKWKK (pen) on the rpVIII is ligated into the fUSE5 phage plasmid genome (Fig. 2) . If the iPhage constructs are properly assembled, generation of iPhage particles is often abundant and nontoxic to the host bacteria K91/kan E. coli. iPhage library titers of 1-5 × 10 10 TU ml − 1 and clone diversity up to 10 9 are routinely obtained and are consistent with the titers generated with the parental phage. Functional assays to evaluate either the correct display of pen and/or the capacity of targeted iPhage to home to different intracellular compartments, such as mitochondria (exemplified in this protocol), can be performed by either infection of host E. coli or by the qPhage method (box 1) and complemented by the iPhage internalization assay (supplementary Fig. 1 and box 3 ) in virtually any cell line 32 . For instance, iPhage particles displaying the SV40 large T-antigen nuclear localization signal (NLS; PKKKRKV) 68 can be enriched specifically in the nuclear fraction of KS1767, whereas parental phage and nontargeted (insertless) iPhage show no substantial enrichment toward any subcellular fraction (Fig. 6a) . (Note that the oligonucleotide sequence encoding the NLS peptide is shown in table 1.) Similarly, fluorescence microscopy reveals that NLS iPhage is specifically directed to the nuclei of live KS1767 cells (Fig. 6b) . Although it is not required, designing and producing iPhage particles displaying a NLS-targeting sequence will allow the investigator to become acquainted with the iPhage technology and related methods before the production and screening of an iPhage library. In addition, NLS-iPhage particles can serve as positive controls for functional assays during receptor identification and validation. Three rounds of synchronous selection (Steps 58-69) are performed to isolate organelle-enriched iPhage clones (Fig. 7a) . The recovered iPhage pool can be evaluated by either infection of host E. coli or by the qPhage method (box 1). After round 3, a marked increase in iPhage particles should be observed in each of the subcellular fractions (Fig. 7b) . Appropriate bioinformatic analyses must be applied to identify enriched sequences. The selected peptide candidate is synthesized by the solid-phase method and used in functional assays as well as for receptor identification.
Box 3 | Subcellular localization of iPhage particles • tIMInG 2 d
Seed 5 × 10 3 KS1767 cells in a 16-well glass chamber plate and allow the cells to grow overnight at 37 °C. The next day, prepare, per well, 1 × 10 9 TU of iPhage particles in 100 µl of MEM containing 2% (vol/vol) FBS (filtered through a 0.22-µm filter). Remove the medium from the overnight-grown culture and add the iPhage particles. Incubate the chamber overnight at 37 °C in a 5% CO 2 -humidified incubator. After incubation, add the desired organelle dye (e.g., Mitotracker dye solution for mitochondria labeling) and incubate the chamber at 37 °C for 30 min. The population of cell membrane-bound phage is removed by washing the cells three times with 200 µl per well of glycine buffer (20 mM glycine; pH 2.3). For each wash, incubate the chamber at room temperature for 3 min under gentle agitation. Glycine is neutralized by washing the chamber three times with 200 µl of PBS and is fixed with 4% (vol/vol) PFA in PBS at room temperature for 15 min. Note that different fixatives may be used, such as methanol or acetone, but conditions will require optimization depending on the organelle dye used. After three washes with PBS, fixed cells are rendered permeable with 200 µl of PBS containing 0.2% (vol/vol) Triton X-100, blocked with 200 µl of PBS containing 1% (wt/vol) BSA and incubated with 100 µl of the primary fd bacteriophage antibody (1:200 dilution) or normal rabbit IgG in PBS containing 1% (wt/vol) BSA for 2 h at room temperature. Next, 100 µl of secondary Alexa Fluor 488 anti-rabbit IgG (1:300) in 1% (wt/vol) BSA-PBS is added to each well, and incubation is continued for 1 h at room temperature in the dark. Cells are washed with PBS, fixed with PBS containing 4% (vol/vol) PFA, mounted in the presence of DAPI and visualized under a fluorescence microscope or by confocal microscopy (supplementary Fig. 1) . ! cautIon PFA is highly toxic. Avoid contact with the eyes, skin and mucous membranes. Use skin and eye protection during PFA manipulation and application. Thus far, several peptides with intracellular homing and biological properties have been identified by this technology (not shown). Figure 7c depicts the intracellular distribution of a biotinylated intracellular ligand peptide (iLP; GKKRYD-HEL) fused to pen. The iLP candidate has a unique, reproducible and specific nuclear membrane distribution in KS1767 cells. After the peptide candidate is characterized in vitro, the peptide is coupled to agarose beads and used to affinity-purify its binding partner or intracellular receptor. Fractions obtained from the affinity chromatography are individually tested against the iPhage candidate (Fig. 7d) . Positive fractions are further analyzed by SDS-PAGE (Fig. 7e) , or alternatively by 2D gel electrophoresis, to identify a distinct set of proteins present in the peptide eluate. Unique bands should be methodically and carefully isolated and analyzed by MS/MS to reveal a list of reasonable receptor candidates. The use of bioinformatic tools (e.g., DAVID, String or IPA) to mine the MS/MS data is encouraged and should be performed at an early stage of the investigation. In summary, our method allows an unbiased combinatorial selection, isolation, identification and validation of intracellular receptors directing iPhage particles or ligand peptides to distinct and specific cell compartments. coMpetInG FInancIal Interests The authors declare competing financial interests: details are available in the online version of the paper.
